email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
211 - 225
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Skyline Approved to Start China Trials of Gene Therapy for Macular Degeneration
$5.00
Available
Belief BioMed Signs up Takeda to Commercialize Gene Therapy for Hemophilia in China
$5.00
Available
KBP Sells Hypertension Candidate for $1.3 Billion to Novo Nordisk
$5.00
Available
Hengrui Out-Licenses its PD-1 for Liver Cancer to Elevar in $1 Billion Deal
$5.00
Available
WuXi Biologics’ Novel Bioprocessing Platform Offers Higher Yields, Lower Costs
$5.00
Available
EpimAb Out-licenses Use of its Bispecific Platform to Almirall in $210 Million Agreement
$5.00
Available
SparX’s Lead Claudin 18.2 mAb Candidate Included in CAR-iNKT Cell Therapy
$5.00
Available
Ascentage Pharma to Start Phase III Trial of Bcl-2 Inhibitor for Leukemia
$5.00
Available
Akeso Reports Positive Data from PD-1/CTLA-4 Bispecific Published in Lancet
$5.00
Available
MediLink Out-Licenses Novel HER3 ADC to BioNTech in $1.1 Billion Agreement
$5.00
Available
Kintor Approved to Begin China Phase II Trial for Pulmonary Fibrosis Candidate
$5.00
Available
Gritgen Advances Hemophilia A Gene Therapy; Completes Manufacturing Plant
$5.00
Available
I-Mab and ABL Bio Report Preliminary Efficacy of Bispecific PD-L1/4-1BB
$5.00
Available
Beijing’s BioMap, an AI Drug Discovery Startup, Signs $1 Billion Deal with Sanofi
$5.00
Available
GenFleet Starts Phase Ib/II Trial of CDK9 Inhibitor for Peripheral T-Cell Lymphomas
$5.00
Available